Medscape

De-escalating GLP-1s to Every-2-Weeks Maintenance Option

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...

Core rises, cushion collapses: India Inc's two-speed revenue challenge in Q2

Core operational revenue shows signs of recovery in Q2, but the sharp drop in other income—the first since at least nine ...
ABS-CBN on MSN

Almost 1.3 million households still without power in Visayas after typhoon onslaught

The National Electrification Administration said there are still flooded areas and roads with debris that prevent crews from ...
Kauppalehti

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

The Phase 2a data1 from initial dosing cohorts marks the first robust demonstration of an oral OX2R agonist addressing wakefulness needs across NT1 patients, who lack endogenous orexin, and the ...

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal a…

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing ...